The ExteNET trial is an international, randomized, double-bind, placebo-controlled, phase 3 trial where researchers presented findings that neratinib, when given for 1 year following trastuzumab-based treatment, showed considerable improvement in disease-free survival in patients with early-stage HER2-positive breast cancer. Researchers of this article state the final evaluation of overall survival from this study. A total of 2,840 patients were enrolled in the study between July 9, 2009 and October 24, 2011, either receiving neratinib (n=1,420) or placebo (n=1,420). The median follow-up was 8.1 years, and 127 patients in the neratinib cohort and 137 patients in the placebo intention-to-treat group had died. The neratinib group experienced a 90.1% eight-year overall survival rate, while the placebo group experienced a 90.2% eight-year overall survival rate.
Reference: Holmes FA, Moy B, Delaloge S, et al; ExteNET Study Group. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-Positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. Eur J Cancer. 2023. doi:10.1016/j.ejca.2023.02.002
Link: https://www.ejcancer.com/article/S0959-8049(23)00063-1/fulltext
